Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

USA - NASDAQ:CRMD - US21900C3088 - Common Stock

11.3 USD
+0.18 (+1.62%)
Last: 9/26/2025, 8:00:00 PM
11.29 USD
-0.01 (-0.09%)
After Hours: 9/26/2025, 8:00:00 PM
Fundamental Rating

7

Overall CRMD gets a fundamental rating of 7 out of 10. We evaluated CRMD against 196 industry peers in the Pharmaceuticals industry. CRMD has an excellent financial health rating, but there are some minor concerns on its profitability. CRMD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make CRMD a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

CRMD had positive earnings in the past year.
In the past year CRMD had a positive cash flow from operations.
CRMD had negative earnings in each of the past 5 years.
In the past 5 years CRMD always reported negative operating cash flow.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CRMD's Return On Assets of 20.25% is amongst the best of the industry. CRMD outperforms 96.94% of its industry peers.
CRMD's Return On Equity of 23.19% is amongst the best of the industry. CRMD outperforms 93.37% of its industry peers.
CRMD has a better Return On Invested Capital (17.64%) than 94.90% of its industry peers.
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROIC 17.64%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

CRMD has a Profit Margin of 42.11%. This is amongst the best in the industry. CRMD outperforms 97.45% of its industry peers.
Looking at the Operating Margin, with a value of 40.60%, CRMD belongs to the top of the industry, outperforming 97.45% of the companies in the same industry.
CRMD has a better Gross Margin (95.62%) than 97.45% of its industry peers.
In the last couple of years the Gross Margin of CRMD has grown nicely.
Industry RankSector Rank
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CRMD is still creating some value.
CRMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRMD has more shares outstanding
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 16.33 indicates that CRMD is not in any danger for bankruptcy at the moment.
CRMD has a better Altman-Z score (16.33) than 88.27% of its industry peers.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.33
ROIC/WACC1.78
WACC9.89%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

CRMD has a Current Ratio of 7.82. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
CRMD has a better Current ratio (7.82) than 77.04% of its industry peers.
A Quick Ratio of 7.52 indicates that CRMD has no problem at all paying its short term obligations.
The Quick ratio of CRMD (7.52) is better than 76.02% of its industry peers.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.52
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 180.65% over the past year.
Looking at the last year, CRMD shows a very strong growth in Revenue. The Revenue has grown by 14970.65%.
Measured over the past years, CRMD shows a very strong growth in Revenue. The Revenue has been growing by 174.29% on average per year.
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%

3.2 Future

Based on estimates for the next years, CRMD will show a very strong growth in Earnings Per Share. The EPS will grow by 55.63% on average per year.
The Revenue is expected to grow by 58.84% on average over the next years. This is a very strong growth
EPS Next Y590.65%
EPS Next 2Y201.92%
EPS Next 3Y113.37%
EPS Next 5Y55.63%
Revenue Next Year488.8%
Revenue Next 2Y206.9%
Revenue Next 3Y115.32%
Revenue Next 5Y58.84%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 15.07, the valuation of CRMD can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 84.69% of the companies listed in the same industry.
CRMD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 4.81, which indicates a rather cheap valuation of CRMD.
96.94% of the companies in the same industry are more expensive than CRMD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.05. CRMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 15.07
Fwd PE 4.81
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 84.69% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CRMD is valued cheaply inside the industry as 81.63% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 27.74
EV/EBITDA 12.47
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CRMD may justify a higher PE ratio.
A more expensive valuation may be justified as CRMD's earnings are expected to grow with 113.37% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y201.92%
EPS Next 3Y113.37%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (9/26/2025, 8:00:00 PM)

After market: 11.29 -0.01 (-0.09%)

11.3

+0.18 (+1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners46.71%
Inst Owner Change49.08%
Ins Owners7.55%
Ins Owner Change5.94%
Market Cap843.54M
Analysts81.54
Price Target20.57 (82.04%)
Short Float %17.26%
Short Ratio3.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.96%
Min EPS beat(2)13.12%
Max EPS beat(2)58.8%
EPS beat(4)4
Avg EPS beat(4)44.57%
Min EPS beat(4)13.12%
Max EPS beat(4)58.8%
EPS beat(8)7
Avg EPS beat(8)23.17%
EPS beat(12)8
Avg EPS beat(12)15.69%
EPS beat(16)11
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)3.69%
Max Revenue beat(2)14.48%
Revenue beat(4)4
Avg Revenue beat(4)9.28%
Min Revenue beat(4)3.62%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.68%
PT rev (3m)22.97%
EPS NQ rev (1m)9.68%
EPS NQ rev (3m)113.55%
EPS NY rev (1m)15.01%
EPS NY rev (3m)98.84%
Revenue NQ rev (1m)11.1%
Revenue NQ rev (3m)69.29%
Revenue NY rev (1m)8.26%
Revenue NY rev (3m)61.5%
Valuation
Industry RankSector Rank
PE 15.07
Fwd PE 4.81
P/S 6.94
P/FCF 27.74
P/OCF 27.69
P/B 3.82
P/tB 3.85
EV/EBITDA 12.47
EPS(TTM)0.75
EY6.64%
EPS(NY)2.35
Fwd EY20.78%
FCF(TTM)0.41
FCFY3.61%
OCF(TTM)0.41
OCFY3.61%
SpS1.63
BVpS2.96
TBVpS2.93
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROCE 22.33%
ROIC 17.64%
ROICexc 129.11%
ROICexgc 137.01%
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
FCFM 25.03%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 10.02%
Cap/Sales 0.04%
Interest Coverage 1343.8
Cash Conversion 61.11%
Profit Quality 59.44%
Current Ratio 7.82
Quick Ratio 7.52
Altman-Z 16.33
F-Score7
WACC9.89%
ROIC/WACC1.78
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
EPS Next Y590.65%
EPS Next 2Y201.92%
EPS Next 3Y113.37%
EPS Next 5Y55.63%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%
Revenue Next Year488.8%
Revenue Next 2Y206.9%
Revenue Next 3Y115.32%
Revenue Next 5Y58.84%
EBIT growth 1Y184.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year651.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y197%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.89%
OCF growth 3YN/A
OCF growth 5YN/A